MEASUREMENT OF ANALYTES IN WHOLE BLOOD AND SERUM

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。拜耳医疗集团已经完成了我们为他们构建的拉曼系统的复制品的改编。这种适应性使其更适合用于他们的狗测试设施。使用这个系统，拉曼非侵入性葡萄糖测量的研究，使用钳夹协议麻醉狗已经开始。光谱实验室人员分析了其中两项研究的数据。根据这些数据开发的交叉验证校准提供了我们认为有希望的结果。在七水平钳夹研究中，第一个样本作为离群值被删除，校准的平均误差（SEV）为18 mg/dL，平均绝对误差为8.5%，R2为0.96。此外，来自狗研究的数据显示出许多与我们在人体测试中看到的相同的特征和问题。我们希望使用这种狗测试功能的有针对性的实验将是我们努力了解这些性能问题的原因的重要资源。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Bayer Healthcare has completed adaptation of the duplicate of our Raman system that we constructed for them. The adaptation made it more suitable for use in their dog testing facility. Using this system, studies of Raman non-invasive glucose measurements using a clamp protocol on anesthetized dogs has been initiated. Spectroscopy Lab personnel have analyzed the data from two of these studies. Cross validated calibrations developed from this data have provided what we believe are promising results. In a seven level clamp study with the first sample removed as an outlier, the calibration has an average error (SEV) of 18 mg/dL, a Mean Absolute Error of 8.5% and an R2 of 0.96. In addition, data from the dog studies exhibited many of the same characteristics and issues that we have seen with our human testing. We expect that targeted experiments using this dog testing capability will be an important resource for us in our effort to understand the causes of these performance issues.